WO2025252117 - SELECTIVE CDK INHIBITOR COMPOUND AND APPLICATION THEREOF
National phase entry is expected:
Publication Number
WO/2025/252117
Publication Date
11.12.2025
International Application No.
PCT/CN2025/099027
International Filing Date
04.06.2025
Title **
[English]
SELECTIVE CDK INHIBITOR COMPOUND AND APPLICATION THEREOF
[French]
COMPOSÉ INHIBITEUR SÉLECTIF DE CDK ET SON APPLICATION
[Chinese]
选择性CDK抑制剂化合物及其应用
Applicants **
SHANGHAI SIMCERE ZAIMING BIOTECHNOLOGY CO., LTD.
Inventors
ZHU, Wei
LI, Zhengtao
TANG, Renhong
Priority Data
202410730128.7
06.06.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1951 | |
| EPO | Filing, Examination, Granting | 15728 | |
| Japan | Filing, Examination, Granting | 2419 | |
| South Korea | Filing, Examination, Granting | 2638 | |
| USA | Filing, Examination, Granting | 5340 |
Total:
28,076
Contact Us
Abstract[English]
Provided is a compound targeting a cyclin-dependent kinase (CDK), and specifically provided is a compound as represented by formula (I), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof. The compound has the substituents and structural features as described in the present application. Also described are a pharmaceutical composition containing the compound of formula (I), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutical application of the compound, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.[French]
L'invention concerne un composé ciblant une kinase dépendante de la cycline (CDK), et spécifiquement un composé tel que représenté par la formule (I), ou un stéréoisomère de celui-ci, ou un sel pharmaceutiquement acceptable de celui-ci. Le composé présente les substituants et les caractéristiques structurales tels que décrits dans la présente demande. L'invention concerne également une composition pharmaceutique contenant le composé de formule (I), ou un stéréoisomère de celui-ci, ou un sel pharmaceutiquement acceptable de celui-ci, et une application pharmaceutique du composé, ou d'un stéréoisomère de celui-ci, ou d'un sel pharmaceutiquement acceptable de celui-ci.[Chinese]
提供了靶向细胞周期蛋白激酶(CDK)的化合物，具体提供了式(I)的化合物或其立体异构体或其药学上可接受的盐，所述化合物具有本申请所述取代基和结构特征。还描述了包含式(I)化合物或其立体异构体或其药学上可接受的盐的药物组合物，以及所述化合物或其立体异构体或其药学上可接受的盐在医药上的应用。